Article Text

Download PDFPDF
Is the periodic repetition of a coagulation check necessary during anti-hepatitis C virus therapy?
  1. F Capra1,
  2. N Nicolini1,
  3. M Franchini2
  1. 1Medicina Interna A, Dipartimento di Scienze Biomediche e Chirurgiche, Università di Verona, Verona, Italy
  2. 2Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy
  1. Correspondence to:
    Dr M Franchini
    Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Piazzale L Scuro, 10, 37134 Verona, Italy; mfranchini{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Peginterferon α and ribavirin have become the mainstay of treatment for chronic hepatitis C virus (HCV) infection.1 However, chronic use of interferon (IFN)-α has been associated with the development of autoimmune disorders, such as systemic lupus erythematosus, autoimmune haemolytic anaemia, and autoimmune thyroiditis. In particular, some reports have documented the development of acquired factor VIII inhibitors in patients receiving IFN-α, including those treated for chronic HCV infection.2–6

We report the case of a …

View Full Text


  • Conflict of interest: None declared.